H.J. Res. 46 would, under chapter 8 of title 5 (the Congressional Review Act), disapprove and render without legal effect the Environmental Protection Agency rule titled “Decabromodiphenyl Ether and Phenol, Isopropylated Phosphate (3:1); Revision to the Regulation of Persistent, Bioaccumulative, and Toxic Chemicals Under the Toxic Substances Control Act (TSCA)” (89 Fed.
Reg. 91486, Nov. 19, 2024).
The resolution’s practical impact, if enacted, is to strip the challenged rule of legal force and to trigger the CRA’s collateral consequence that the agency may not reissue the rule in substantially the same form absent explicit congressional authorization. That outcome removes the federal regulatory requirements the rule imposed, shifts regulatory pressure onto states and private actors, and raises compliance and liability questions for manufacturers, downstream users, waste handlers, and EPA itself.
At a Glance
What It Does
The joint resolution invokes the Congressional Review Act to disapprove a specified EPA rule addressing two persistent, bioaccumulative, toxic (PBT) chemicals and declares that rule to have "no force or effect." It relies on 5 U.S.C. chapter 8 to produce that nullification and its collateral prohibition on reissuing a substantially similar rule without congressional authorization.
Who It Affects
Chemical manufacturers, importers, processors, downstream product makers that use Decabromodiphenyl Ether (DecaBDE) or Phenol, Isopropylated Phosphate (3:1) (PIP (3:1)), waste managers, and state environmental agencies would be directly affected. EPA’s regulatory program under TSCA Section 6 and compliance officers whose operations would have been constrained by the rule also face direct impact.
Why It Matters
The bill uses a blunt statutory tool to eliminate a rule addressing PBT risks rather than amending TSCA or EPA’s risk determinations, which leaves a substantive public-health regulatory gap. For businesses and regulators, disapproval changes compliance obligations, reallocates regulatory authority pressure to states, and creates legal uncertainty about whether and how EPA can address the underlying chemical risks going forward.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
H.J. Res. 46 is straightforward in form: it names the EPA rule published at 89 Fed.
Reg. 91486 (Nov. 19, 2024) and states that Congress disapproves that rule under the Congressional Review Act. The resolution does not detail why Congress disapproves; its operative effect is statutory and mechanical — to remove the rule from the body of enforceable federal regulations if the resolution becomes law.
Under the CRA, a successful disapproval resolution does more than simply repeal the challenged regulation. It also invokes a statutory bar that prevents the agency from issuing a replacement rule that is "substantially the same" as the disapproved one unless Congress enacts affirmative legislation authorizing that action.
That bar constrains EPA’s near-term ability to pursue the same regulatory design to control DecaBDE and PIP (3:1) without new congressional authorization.On the ground, the immediate legal consequence is that obligations, prohibitions, or restrictions the EPA rule would have imposed no longer stand as federal requirements (subject to the timing and constitutional mechanics of enactment and any legal challenges). Regulated entities therefore lose the federal compulsion to change operations that the rule would have imposed, but the underlying public-health concerns identified in the EPA record remain unresolved.
States can still adopt their own restrictions under state authority, and EPA can pursue alternative regulatory approaches that are not "substantially the same," though those paths carry litigation and resource risks.For compliance officers and corporate counsel, the resolution creates practical uncertainty. Companies that had begun compliance or reformulation will face potential stranded costs; supply-chain decisions tied to the rule may need re-evaluation; and enforcement priorities at EPA will shift.
Meanwhile, environmental and public-health advocates will likely press states or pursue other federal channels to address the original hazard findings that motivated EPA’s PBT action.
The Five Things You Need to Know
The resolution expressly disapproves the EPA rule titled for Decabromodiphenyl Ether and Phenol, Isopropylated Phosphate (3:1), referencing the Federal Register citation 89 Fed. Reg. 91486 (Nov. 19, 2024).
It invokes chapter 8 of title 5, U.S. Code — the Congressional Review Act (CRA) — as the statutory vehicle for disapproval and states the rule "shall have no force or effect.", A CRA disapproval carries a collateral bar: the agency cannot promulgate a rule in "substantially the same" form as the disapproved rule without an act of Congress authorizing the reissuance.
The resolution targets EPA action under TSCA that addressed persistent, bioaccumulative, and toxic (PBT) chemicals, but it does not itself alter TSCA’s statutory text or EPA’s underlying risk determinations.
If enacted, parties that had adjusted operations to comply with the EPA rule would lose the federal obligation — creating potential stranded compliance costs and shifting regulatory responsibility to states or alternative federal actions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Identifies the targeted EPA rule
This opening text names the specific rule by title and Federal Register citation (89 Fed. Reg. 91486, Nov. 19, 2024). That identification is legally significant because CRA disapproval applies only to the particular rule submitted to Congress; the resolution does not purport to disapprove other EPA actions or TSCA authorities. For practitioners, the precise citation limits the resolution’s reach to that administrative record.
Congress disapproves the rule and strips its force
The single operative provision declares that Congress disapproves the named EPA rule and states that the rule "shall have no force or effect." Practically, that removes the regulation from the enforceable Code of Federal Regulations if the resolution is enacted. The clause is terse: it does not specify remedial steps, implementation timelines, or transitional arrangements for entities that had begun compliance before the disapproval takes effect.
Uses chapter 8 of title 5 (Congressional Review Act)
The resolution explicitly relies on the CRA (5 U.S.C. chapter 8) to accomplish disapproval. Under CRA mechanics, disapproval not only nullifies the rule but also triggers the statute’s restriction on reissuing a substantially similar regulation absent a new act of Congress. That legal consequence is not restated in the text of the resolution but follows automatically from the CRA regime; it shapes EPA’s options post-disapproval.
This bill is one of many.
Codify tracks hundreds of bills on Environment across all five countries.
Explore Environment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Chemical manufacturers of DecaBDE and PIP (3:1): They avoid the new federal restrictions the EPA rule would have imposed, preserving existing manufacturing, processing, and import practices until and unless other legal constraints apply.
- Downstream product makers (electronics, textiles, adhesives, and other users of flame retardants and plasticizers): They retain access to existing materials and avoid immediate reformulation costs that the rule might have required.
- Distributors and importers that would have faced labeling, notification, or reporting changes: They avoid new compliance duties tied to the federal rule, reducing short-term administrative and recordkeeping expenses.
- Businesses that had not yet begun compliance transitions: They gain regulatory stability in the short term because they will not have to implement the rule’s obligations unless another regulation or state action fills the gap.
Who Bears the Cost
- Environmental and public-health stakeholders: They lose a federal regulatory tool aimed at reducing exposures to PBT chemicals, potentially prolonging population and ecological exposure risks.
- State environmental agencies and legislatures: States may face pressure to adopt their own restrictions, imposing administrative and budgetary costs to fill a federal regulatory void.
- EPA and federal regulators: The agency loses an implemented regulatory lever and faces constraints on reissuing similar protections without Congress, complicating programmatic strategies under TSCA.
- Companies and organizations that already invested in compliance or reformulation: Entities that incurred costs to meet the now-disapproved rule potentially carry stranded costs and face commercial disadvantage relative to competitors that did not act early.
- Waste managers, recyclers, and public utilities: Continued use of the chemicals can perpetuate legacy disposal and contamination challenges, shifting remediation burdens onto local actors.
Key Issues
The Core Tension
The central dilemma is between congressional oversight that can rapidly undo agency action and the need for durable, technically grounded regulation of chemicals that pose long-term health and environmental risks; the CRA lets Congress remove a regulatory tool quickly, but it does not itself provide the scientific, administrative, or budgetary pathway needed to replace that tool with an alternative that addresses the same underlying hazards.
The resolution exercises the CRA’s blunt instrument: it eradicates a specific rule without resolving the underlying scientific or risk-management questions that motivated EPA’s action. That creates an implementation tension.
If the EPA’s record established risks from DecaBDE and PIP (3:1), removing the rule leaves those risks unaddressed at the federal level; if the record was procedurally or legally vulnerable, disapproval removes a contested tool rather than correcting the underlying record. Either way, the result is a regulatory gap that states, industry standards bodies, or litigation may try to fill.
A second practical tension is the CRA’s ‘‘substantially the same’’ bar. The statute’s prohibition is conceptually clear but operationally slippery: it invites litigation over whether a later EPA rule crosses the line.
That uncertainty increases the transactional and litigation costs of any alternative federal approach. Moreover, companies that already changed products or supply chains face stranded investments if the rule is nullified, creating fairness and market-competition concerns that Congress did not address in the resolution.
Finally, the resolution does not allocate resources or provide a policy alternative for managing PBT chemicals, leaving regulators and stakeholders to sort out the technical, financial, and legal consequences in an ad hoc way.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.